Artificial Intelligence for Risk Assessment on Primary Prevention of Coronary Artery Disease

Author:

Chen Shang-FuORCID,Loguercio Salvatore,Chen Kai-Yu,Lee Sang Eun,Park Jun-Bean,Liu Shuchen,Sadaei Hossein Javedani,Torkamani Ali

Abstract

Abstract Purpose of Review Coronary artery disease (CAD) is a common and etiologically complex disease worldwide. Current guidelines for primary prevention, or the prevention of a first acute event, include relatively simple risk assessment and leave substantial room for improvement both for risk ascertainment and selection of prevention strategies. Here, we review how advances in big data and predictive modeling foreshadow a promising future of improved risk assessment and precision medicine for CAD. Recent Findings Artificial intelligence (AI) has improved the utility of high dimensional data, providing an opportunity to better understand the interplay between numerous CAD risk factors. Beyond applications of AI in cardiac imaging, the vanguard application of AI in healthcare, recent translational research is also revealing a promising path for AI in multi-modal risk prediction using standard biomarkers, genetic and other omics technologies, a variety of biosensors, and unstructured data from electronic health records (EHRs). However, gaps remain in clinical validation of AI models, most notably in the actionability of complex risk prediction for more precise therapeutic interventions. Summary The recent availability of nation-scale biobank datasets has provided a tremendous opportunity to richly characterize longitudinal health trajectories using health data collected at home, at laboratories, and through clinic visits. The ever-growing availability of deep genotype-phenotype data is poised to drive a transition from simple risk prediction algorithms to complex, “data-hungry,” AI models in clinical decision-making. While AI models provide the means to incorporate essentially all risk factors into comprehensive risk prediction frameworks, there remains a need to wrap these predictions in interpretable frameworks that map to our understanding of underlying biological mechanisms and associated personalized intervention. This review explores recent advances in the role of machine learning and AI in CAD primary prevention and highlights current strengths as well as limitations mediating potential future applications.

Funder

Foundation for the National Institutes of Health

Scripps Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference270 articles.

1. Tsao CW, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:E153–639.

2. Timmis A, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43:716–99.

3. Libby P. The vascular biology of atherosclerosis. In: Braunwald’s heart disease, 2 vol set: a textbook of cardiovascular medicine 12th edition. Elsevier. 2021. 425–441.

4. Morrow D.A, de Lemos J. Stable ischemic heart disease. In: Braunwald’s heart disease, 2 vol set: a textbook of cardiovascular medicine 12th edition. Elsevier. 2021. 739–785.

5. Duncker DJ, Canty Jr JM. Coronary blood flow and myocardioal ischemia. In: Braunwald’s heart disease, 2 vol set: a textbook of cardiovascular medicine 12th edition. Elsevier, 2021. 609–635.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3